TY - JOUR
T1 - World Workshop on Oral Medicine VI
T2 - A systematic review of the treatment of mucocutaneous pemphigus vulgaris
AU - McMillan, R.
AU - Taylor, J.
AU - Shephard, M.
AU - Ahmed, R.
AU - Carrozzo, M.
AU - Setterfield, J.
AU - Grando, S.
AU - Mignogna, M.
AU - Kuten-Shorrer, M.
AU - Musbah, T.
AU - Elia, A.
AU - McGowan, R.
AU - Kerr, A. R.
AU - Greenberg, M. S.
AU - Hodgson, T.
AU - Sirois, D.
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015
Y1 - 2015
N2 - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.
AB - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.
UR - http://www.scopus.com/inward/record.url?scp=84947041333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947041333&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2015.01.022
DO - 10.1016/j.oooo.2015.01.022
M3 - Article
C2 - 25934414
AN - SCOPUS:84947041333
SN - 2212-4403
VL - 120
SP - 132-142.e61
JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
IS - 2
ER -